awmsg logo



safinamide (Xadago®)


Reference No. 2493

Publication date:
30/06/2015


Appraisal information

safinamide (Xadago®) 50 mg film-coated tablet
safinamide (Xadago®) 100 mg film-coated tablet


Company: Zambon SpA
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, safinamide (Xadago®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with idiopathic Parkinson's disease as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson's disease medicinal products in mid- to late-stage fluctuating patients.
Statement of Advice (SOA)
Download